NETest Supporting Data

The NETest is a novel blood-based laboratory developed test (LDT), a molecular diagnostic, that provides sensitive and specific information with respect to a neuroendocrine tumor status. The test is unique in that it uses 51 neuroendocrine tumor gene transcripts and novel state-of-the-art molecular biomarker analyses developed by Wren scientists. This allows us to monitor neuroendocrine tumor gene activity levels. Four areas that the NETest has demonstrated clinical utility include as a diagnostic, as a prognostic, as a monitor of therapy and as a predictor of therapy.
A scientist pipetting DNA samples into a tube.A scientist pipetting DNA samples into a tube.

A. Use as a diagnostic:

The following manuscripts identify the NETest is more accurate (sensitive) than any other biomarker for the diagnosis of NET disease. These include initial and independent validation that the NETest is a bona fide NET diagnostic.

B. Use as a prognostic:

The following manuscripts demonstrate that elevated NETest scores are associated with poor progression free survival and can be used to identify those in whom disease will progress. Low scores, in contrast, are concordant with disease stability.

C. Monitoring therapy:

The following manuscripts demonstrate the clinical utility of the NETest in patients treated with somatostatin analogs or radionuclide therapy.

D. Utility as a companion diagnostic:

These manuscripts identify the clinical utility of the NETest in predicting response to radionuclide therapy.